Overview

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles
Phase:
Phase 3
Details
Lead Sponsor:
Mylan Inc.
Collaborator:
Mylan Technologies Inc.
Treatments:
Contraceptive Agents